# EDGAR Filing Document

**Accession Number:** 0000764180
**File Stem:** 0000764180-23-000012
**Filing Date:** 2023-2
**Character Count:** 92598
**Document Hash:** 15913375a338826897a9e7009e4bf74c
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000764180-23-000012.hdr.sgml**: 20230201

**ACCESSION NUMBER**: 0000764180-23-000012

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 15

**CONFORMED PERIOD OF REPORT**: 20230131

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Other Events

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230201

**DATE AS OF CHANGE**: 20230201

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ALTRIA GROUP, INC.
- **CENTRAL INDEX KEY:** 0000764180
- **STANDARD INDUSTRIAL CLASSIFICATION:** CIGARETTES [2111]
- **IRS NUMBER:** 133260245
- **STATE OF INCORPORATION:** VA
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-08940
- **FILM NUMBER:** 23574710

**BUSINESS ADDRESS:**
- **STREET 1:** 6601 WEST BROAD STREET
- **CITY:** RICHMOND
- **STATE:** VA
- **ZIP:** 23230
- **BUSINESS PHONE:** (804) 274-2200

**MAIL ADDRESS:**
- **STREET 1:** 6601 WEST BROAD STREET
- **CITY:** RICHMOND
- **STATE:** VA
- **ZIP:** 23230

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ALTRIA GROUP INC
- **DATE OF NAME CHANGE:** 20030127

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** PHILIP MORRIS COMPANIES INC
- **DATE OF NAME CHANGE:** 19920703

?xml version="1.0" ? mo-20230131

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**____________________________________________________________________________________________________________**

**FORM 8-K**

**________________________________________________________________________________________________________________**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of**

**The Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): January 31, 2023** 

**________________________________________________________________________________________________________________**

**ALTRIA GROUP, INC.** 

**(Exact name of registrant as specified in its charter)** 

**______________________________________________________________________________________________________________**

---

| | | |
|:---|:---|:---|
| **Virginia** | **1-08940** | **13-3260245** |
| **(State or other jurisdiction<br>of incorporation)** | **(Commission File Number)** | **(I.R.S. Employer<br>Identification No.)** |

---

---

| | | | |
|:---|:---|:---|:---|
| **6601 West Broad Street,** | **Richmond,** | **Virginia** | **23230** |
| **(Address of principal executive offices)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;** | | | **(Zip Code)** |

---

**Registrant's telephone number, including area code: (804) 274-2200** 

**_______________________________________________________________________________________________________________**

**(Former name or former address, if changed since last report.)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Title of each class&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;  | Trading Symbols | Name of each exchange on which registered |
| Common Stock, $0.33 1/3 par value | MO | New York Stock Exchange |
| &nbsp;&nbsp;1.000% Notes due 2023 | MO23A | New York Stock Exchange |
| &nbsp;&nbsp;1.700% Notes due 2025 | MO25 | New York Stock Exchange |
| &nbsp;&nbsp;2.200% Notes due 2027 | MO27 | New York Stock Exchange |
| &nbsp;&nbsp;3.125% Notes due 2031 | MO31 | New York Stock Exchange |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. □

------

**Item 2.02.&nbsp;&nbsp;&nbsp;&nbsp;Results of Operations and Financial Condition.**

On February 1, 2023, Altria Group, Inc. ("Altria") issued a press release announcing its financial results for the year ended December 31, 2022. A copy of the press release is attached as Exhibit 99.1 and is incorporated by reference in this Item 2.02.

In accordance with General Instruction B.2 of Form 8-K, the information in Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. The information in Item 2.02 of this Current Report on Form 8-K shall not be incorporated by reference into any filing or other document pursuant to the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing or document.

**Item 8.01.&nbsp;&nbsp;&nbsp;&nbsp;Other Events.**

On January 31, 2023, Altria's Board of Directors (the "Board") authorized a new $1 billion share repurchase program. The timing of share repurchases under this program depends upon marketplace conditions and other factors, and the program remains subject to the discretion of the Board.

**Item 9.01.**&nbsp;&nbsp;&nbsp;&nbsp;**Financial Statements and Exhibits.**

---

| | | |
|:---|:---|:---|
| (d) | <u>Exhibits</u> | |
| | 99.1 | <u>[Altria Group, Inc. Press Release, dated](exhibit991erq42022.htm)[February](exhibit991erq42022.htm)[1](exhibit991erq42022.htm)[, 2023](exhibit991erq42022.htm)[(furnished under Item 2.02)](exhibit991erq42022.htm)</u>  |
| | 104 | The cover page from this Current Report on Form 8-K, formatted in Inline XBRL (included as Exhibit 101) |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | |
|:---|:---|
| ALTRIA GROUP, INC. | ALTRIA GROUP, INC. |
| By: | <u>/s/ W. HILDEBRANDT SURGNER, JR.</u> |
| Name: | W. Hildebrandt Surgner, Jr. |
| Title: | Vice President, Corporate Secretary and |
|  | Associate General Counsel |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

DATE:&nbsp;&nbsp;&nbsp;&nbsp;February 1, 2023

## Exhibit 99.1

**Exhibit 99.1**

![altriamosaica62.jpg](altriamosaica62.jpg)

**ALTRIA REPORTS 2022 FOURTH-QUARTER AND FULL-YEAR RESULTS;** 

**PROVIDES 2023 FULL-YEAR EARNINGS GUIDANCE; ANNOUNCES NEW $1 BILLION SHARE REPURCHASE PROGRAM**

RICHMOND, Va. - February 1, 2023 - Altria Group, Inc. (NYSE: MO) today reports our 2022 fourth-quarter and full-year business results and provides our guidance for 2023 full-year adjusted diluted earnings per share (EPS).

"It was an exciting year for Altria as our businesses delivered strong financial performance, and we continued to strategically invest toward our Vision," said Billy Gifford, Altria's Chief Executive Officer. "We generated strong adjusted diluted EPS growth of 5% and made meaningful progress in several areas of our smoke-free portfolio."

"Our plans for 2023 include a continuation of our strategy to balance earnings growth and shareholder returns with strategic investments toward our Vision. We expect to deliver 2023 full-year adjusted diluted EPS in a range of $4.98 to $5.13, representing a growth rate of 3% to 6% from a base of $4.84 in 2022."

**Altria Headline Financials**<sup>1</sup><br>

---

| | | | | |
|:---|:---|:---|:---|:---|
| ($ in millions, except per share data) | **Q4 2022** | **Change vs. <br>Q4 2021** | **Full Year 2022** | **Change vs. <br>Full Year 2021** |
| &nbsp;&nbsp;&nbsp;Net revenues | $6111 | **(2.3)%** | $25096 | **(3.5)%** |
| &nbsp;&nbsp;&nbsp;Revenues net of excise taxes | $5083 | **(0.1)%** | $20688 | **(2.0)%** |
| &nbsp;&nbsp;&nbsp;Reported tax rate | 0.5% | **(28.3) pp** | 22.0% | **(13.3) pp** |
| &nbsp;&nbsp;&nbsp;Adjusted tax rate | 25.0% | **(0.5) pp** | 24.9% | **(0.2) pp** |
| &nbsp;&nbsp;Reported diluted EPS<sup>2</sup> | $1.50 | **70.5%** | $3.19 | **100%+** |
| &nbsp;&nbsp;Adjusted diluted EPS<sup>2</sup> | $1.18 | **8.3%** | $4.84 | **5.0%** |

---

<sup>1</sup> *"Adjusted" financial measures presented in this release exclude the impact of special items. See "Basis of Presentation" for more information.*

<sup>2</sup> *"EPS" represents diluted earnings (losses) per share attributable to Altria.*

As previously announced, a conference call with the investment community and news media will be webcast on February 1, 2023 at 9:00 a.m. Eastern Time. Access to the webcast is available at www.altria.com/webcasts.

6601 West Broad Street, Richmond VA 23230

------

**Cash Returns to Shareholders and Capital Markets Activity**

***Share Repurchase Program***

***•*** We completed our previously authorized $3.5 billion share repurchase program. In the fourth quarter, we repurchased 8.3 million shares at an average price of $45.09, for a total cost of $374 million. For the full year, we repurchased 38.1 million shares at an average price of $47.83, for a total cost of $1.8 billion.

***•*** Our Board of Directors (Board) authorized a new $1 billion share repurchase program, which we expect to complete by December 31, 2023. Share repurchases depend on marketplace conditions and other factors, and the program remains subject to the discretion of our Board.

***Dividends***

***•*** We paid dividends of $1.7 billion in the fourth quarter and $6.6 billion for the full year.

***•*** We maintain our long-term objective of a dividend payout ratio target of approximately 80% of our adjusted diluted EPS. Future dividend payments remain subject to the discretion of our Board.

***Capital Markets Activity***

***•*** We expect to retire approximately $1.3 billion of notes coming due later this month with available cash.

**Macroeconomic and Geopolitical Conditions Impacting Our Businesses**

***Impact on Tobacco Business Operations***

***•*** In 2022, our businesses were not materially impacted by increased costs resulting from global supply chain challenges and high inflation.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;***Impact on Adult Tobacco Consumers (ATCs)***

• In 2022, we believe high rates of inflation impacted ATC behaviors, discretionary income and spending. As a result, our businesses and the industry experienced elevated volume declines, and we observed accelerated share growth in discount cigarettes. Despite these factors, our leading tobacco brands remained resilient and we continued to observe significant brand loyalty in the tobacco space overall.

**Philip Morris Capital Corporation Update**

***•*** As of December 31, 2022, we completed the wind-down of Philip Morris Capital Corporation (PMCC) and no finance assets remain.

**Environmental, Social and Governance (ESG)**

Our Corporate Responsibility Focus Areas are: (i) reduce the harm of tobacco products, (ii) prevent underage use, (iii) protect the environment, (iv) drive responsibility through our value chain, (v) support our people and communities and (vi) engage and lead responsibly. Our corporate responsibility reports are available on the Corporate Responsibility section of www.altria.com.

***•*** Our responsibility efforts and recognitions from 2022 include the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;◦ We recently announced that we will conduct an equity and civil rights assessment (Assessment). The Assessment follows last year's passage of a shareholder proposal recommending Altria commission a civil rights equity audit and seeks to address feedback received from recent robust shareholder engagement. We believe the Assessment will identify opportunities to accelerate progress toward our 2025 Corporate Responsibility focus area goals, enhance stakeholder alignment and promote transparency.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;◦ Continued to support efforts to reduce youth tobacco use. Today, underage use of conventional tobacco products is at the lowest levels in a generation. The 2022 Monitoring the Future (MTF) study estimates youth smoking rates to be 2.1%, a nearly 93% reduction from its 1997 peak of 28.3%. Prevalence of past 30-day nicotine vaping among youth is 13.8% in 2022 versus its 2019 peak of 18.1%. MTF surveys 8<sup>th</sup>, 10<sup>th</sup> and 12<sup>th</sup> graders. Rates reported are for 8<sup>th</sup>, 10<sup>th</sup> and 12<sup>th</sup> graders combined.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;◦ Continued to demonstrate environmental leadership with recognition from CDP Global, a non-profit that runs a global disclosure system on managing environmental impact, for addressing climate change (A-) and protecting water security (A-), and improved our rating for addressing the drivers of deforestation (B).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;◦ For the fourth consecutive year, we were chosen as one of the "Best-of-the-Best" Corporations for Inclusion by the National Business Inclusion Consortium. The Best-of-the-Best designation honors corporations for their commitment to America's diverse employees and business owners.

**2023 Full-Year Guidance**

We expect our 2023 full-year adjusted diluted EPS to be in a range of $4.98 to $5.13, representing a growth rate of 3% to 6% from an adjusted diluted EPS base of $4.84 in 2022. While the 2023 full-year adjusted diluted EPS guidance accounts for a range of scenarios, the external environment remains dynamic. We will continue to monitor conditions related to (i) the economy, including the impact of high inflation, rising interest rates and global supply chain disruptions, (ii) ATC dynamics, including disposable income, purchasing patterns and adoption of smoke-free products, and (iii) regulatory and legislative developments.

Our 2023 full-year adjusted diluted EPS guidance range includes planned investments in support of our Vision, such as (i) continued smoke-free product research, development and regulatory preparation expenses, (ii) enhancement of our digital consumer engagement system and (iii) marketplace activities in support of our smoke-free products. The guidance range also includes lower expected net periodic benefit income due to market factors, including higher interest rates, and the impact of the 2022 completion of the PMCC wind-down.

We expect our 2023 full-year adjusted effective tax rate will be in a range of 24.5% to 25.5%. We also expect our 2023 capital expenditures to be between $175 million and $225 million and 2023 depreciation and amortization expenses of approximately $230 million.

*Our full-year adjusted diluted EPS guidance range and full-year forecast for our adjusted effective tax rate exclude the impact of certain income and expense items that management believes are not part of underlying operations. These items may include, for example, loss on early extinguishment of debt, restructuring charges, asset impairment charges, acquisition-related and disposition-related costs, equity investment-related special items (including any changes in fair value of our equity investment recorded at fair value and any changes in the fair value of related warrants and preemptive rights), certain income tax items, charges associated with tobacco and health and certain other litigation items, and resolutions of certain non-participating manufacturer (NPM) adjustment disputes under the MSA (such dispute resolutions are referred to as NPM Adjustment Items). See Table 1 below for the income and expense items for the full-year 2022.*

*Our management cannot estimate on a forward-looking basis the impact of certain income and expense items, including those items noted in the preceding paragraph, on our reported diluted EPS or our reported effective tax rate because these items, which could be significant, may be unusual or infrequent, are difficult to predict and may be highly variable. As a result, we do not provide a corresponding U.S. generally accepted accounting principles (GAAP) measure for, or reconciliation to, our adjusted diluted EPS guidance or our adjusted effective tax rate forecast.*

------

**ALTRIA GROUP, INC.**

*See* "*Basis of Presentation*" *below for an explanation of financial measures and reporting segments discussed in this release.*

**Financial Performance**

**Fourth Quarter**

***•*** Net revenues decreased 2.3% to $6.1 billion, primarily driven by lower net revenues in the smokeable products segment. Revenues net of excise taxes were essentially unchanged at $5.1 billion.

***•*** Reported diluted EPS increased 70.5% to $1.50, primarily driven by favorable income tax items, 2021 Cronos-related special items, higher reported operating companies income (OCI), 2021 ABI-related special items, fewer shares outstanding and favorable interest expense, partially offset by 2022 changes in the estimated fair value of our investment in JUUL (including the corresponding adjustment for a tax valuation allowance).

***•*** Adjusted diluted EPS increased 8.3% to $1.18, primarily driven by higher adjusted OCI, fewer shares outstanding and favorable interest expense.

**Full Year**

***•*** Net revenues decreased 3.5% to $25.1 billion, primarily driven by the sale of our former Ste. Michelle wine business in October 2021 and lower net revenues in the smokeable products segment. Revenues net of excise taxes decreased 2.0% to $20.7 billion.

***•*** Reported diluted EPS increased 100%+ to $3.19 primarily driven by lower reported losses from our investment in ABI (due primarily to a lower impairment of our investment in ABI), favorable income tax items, 2021 losses on early extinguishment of debt, lower losses from Cronos-related special items, higher reported OCI, fewer shares outstanding and favorable interest expense, partially offset by 2022 changes in the estimated fair value of our investment in JUUL (including the corresponding adjustment for a tax valuation allowance).

***•*** Adjusted diluted EPS increased 5.0% to $4.84, primarily driven by fewer shares outstanding, higher adjusted OCI and favorable interest expense.

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **Table 1 - Altria's Adjusted Results** | **Table 1 - Altria's Adjusted Results** | **Table 1 - Altria's Adjusted Results** | | | | |
| | **Fourth Quarter** | **Fourth Quarter** | **Fourth Quarter** | **Full Year** | **Full Year** | **Full Year** |
|  | **2022** | **2021** | **Change** | **2022** | **2021** | **Change** |
| **Reported diluted EPS** | $**1.50** | $**0.88** | **70.5%** | $**3.19** | $**1.34** | **100%+** |
| NPM Adjustment Items |  |  |  | (0.03) | (0.03) |  |
| Asset impairment, exit, implementation, acquisition and disposition-related costs |  |  |  |  | 0.05 |  |
| Tobacco and health and certain other litigation items | 0.01 | 0.02 |  | 0.05 | 0.07 |  |
| JUUL changes in fair value | 0.06 |  |  | 0.81 |  |  |
| ABI-related special items |  | 0.04 |  | 1.12 | 2.66 |  |
| Cronos-related special items |  | 0.15 |  | 0.10 | 0.25 |  |
| Loss on early extinguishment of debt |  |  |  |  | 0.27 |  |
| Income tax items | (0.39) |  |  | (0.40) |  |  |
| **Adjusted diluted EPS** | $**1.18** | $**1.09** | **8.3%** | $**4.84** | $**4.61** | **5.0%** |

---

*Note: For details of pre-tax, tax and after-tax amounts, see Schedules 7 and 9.*

------

**Special Items**

*The EPS impact of the following special items is shown in Table 1 and Schedules 6, 7, 8 and 9.*

***NPM Adjustment Items***

• For the full-year 2022, we recorded pre-tax income of $68 million (or $0.03 per share) for NPM Adjustment Items and related interest, including $63 million recorded as a reduction to cost of sales in the smokeable products segment and $5 million recorded as interest income.

• For the full-year 2021, we recorded pre-tax income of $76 million (or $0.03 per share) for NPM Adjustment Items and related interest, including $53 million recorded as a reduction to cost of sales in the smokeable products segment and $23 million recorded as interest income.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;***Asset Impairment, Exit, Implementation, Acquisition and Disposition-Related Costs***

• For the full-year 2021, we recorded pre-tax charges of $120 million (or $0.05 per share), due primarily to charges associated with the sale of our former Ste. Michelle wine business and acquisition-related costs for the settlement of an arbitration related to the 2019 *on!* transaction.

***Tobacco and Health and Certain Other Litigation Items***

***•*** In the fourth quarter and for full-year 2022, we recorded pre-tax charges of $30 million (or $0.01 per share) and $131 million (or $0.05 per share), respectively, for tobacco and health and certain other litigation items and related interest costs.

***•*** In the fourth quarter and for full-year 2021, we recorded pre-tax charges of $34 million (or $0.02 per share) and $182 million (or $0.07 per share), respectively, for tobacco and health and certain other litigation items and related interest costs.

***JUUL Changes in Fair Value***

We recorded non-cash, pre-tax unrealized (income) losses from investments in equity securities as a result of changes in the estimated fair value of our investment in JUUL consisting of the following:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Fourth Quarter** | **Fourth Quarter** | **Full Year** | **Full Year** |
| **($ in millions, except per share data)** | **2022** | **2021** | **2022** | **2021** |
| &nbsp;&nbsp;&nbsp;(Income) losses from investments in <br>equity securities | $100 | $— | $1455 | $— |
| Losses per share | $0.06 | $— | $0.81 | $— |

---

We recorded corresponding adjustments to the JUUL tax valuation allowance in 2022. As of December 31, 2022, the estimated fair value of our investment in JUUL was $250 million.

***ABI-Related Special Items***

• In the fourth quarter of 2021, equity earnings from ABI included net pre-tax charges of $92 million (or $0.04 per share), substantially all of which related to ABI's mark-to-market losses on certain ABI financial instruments associated with share commitments.

***•*** For the full-year 2022 and 2021, equity earnings from ABI included net pre-tax losses of $2.5 billion (or $1.12 per share) and $6.2 billion (or $2.66 per share), respectively, substantially all of which related to impairments of our investment in ABI.

The ABI-related special items above include our respective share of the amounts recorded by ABI and additional adjustments related to (i) conversion from international financial reporting standards to GAAP and (ii) adjustments to our investment required under the equity method of accounting.

------

***Cronos-Related Special Items***

We recorded net pre-tax expense consisting of the following:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Fourth Quarter** | **Fourth Quarter** | **Full Year** | **Full Year** |
| **($ in millions, except per share data)** | **2022** | **2021** | **2022** | **2021** |
| Loss on Cronos-related financial instruments <sup>1</sup> | $1 | $20 | $15 | $148 |
| &nbsp;&nbsp;&nbsp;&nbsp;(Income) losses from investments in equity <br>securities <sup>2</sup> | 5 | 246 | 171 | 318 |
| Total Cronos-related special items - (income) expense | $6 | $266 | $186 | $466 |
| Losses per share | $— | $0.15 | $0.10 | $0.25 |

---

<sup>1</sup> Amounts are related to the non-cash change in the fair value of the warrant (which we irrevocably abandoned in the fourth quarter of 2022) and certain anti-dilution protections.

<sup>2</sup> Amounts include our share of special items recorded by Cronos and additional adjustments, if required under the equity method of accounting, related to our investment in Cronos including the $107 million and $205 million non-cash, pre-tax impairment of our investment in Cronos for the years ended 2022 and 2021, respectively.

We recorded corresponding adjustments to the Cronos tax valuation allowance in 2022 and 2021 relating to the special items.

***Loss on Early Extinguishment of Debt***

***•*** For the full-year 2021, we recorded pre-tax losses on early extinguishment of debt of $649 million (or $0.27 per share).

***Income Tax Items***

• In the fourth quarter and for full-year 2022, we recorded tax items of $696 million (or $0.39 per share) and $729 million (or $0.40 per share), respectively, due primarily to the release of valuation allowances on deferred tax assets related to a portion of our investment in JUUL and our Cronos warrant (which we irrevocably abandoned in the fourth quarter of 2022) due to the anticipated ability to utilize these losses.

------

**SMOKEABLE PRODUCTS**

**Revenues and OCI**

**Fourth Quarter**

***•*** Net revenues decreased 2.4%, primarily driven by lower shipment volume, partially offset by higher pricing and lower promotional investments. Revenues net of excise taxes were essentially unchanged.

***•*** Reported OCI increased 3.3%, primarily driven by higher pricing, lower promotional investments and lower per unit settlement charges, partially offset by lower shipment volume and higher costs (including higher tobacco and health and certain other litigation items).

***•*** Adjusted OCI increased 4.0%, primarily driven by higher pricing, lower promotional investments and lower per unit settlement charges, partially offset by lower shipment volume and higher costs. Adjusted OCI margins increased by 2.2 percentage points to 58.4%.

**Full Year**

***•*** Net revenues decreased 1.7%, primarily driven by lower shipment volume, partially offset by higher pricing and lower promotional investments. Revenues net of excise taxes increased 0.4%.

• Reported and adjusted OCI increased 2.8% and 2.9%, respectively, primarily driven by higher pricing and lower promotional investments, partially offset by lower shipment volume, higher costs and higher per unit settlement charges. Adjusted OCI margins increased by 1.4 percentage points to 59%.

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **Table 2 - Smokeable Products: Revenues and OCI ($ in millions)** | **Table 2 - Smokeable Products: Revenues and OCI ($ in millions)** | **Table 2 - Smokeable Products: Revenues and OCI ($ in millions)** | | | | |
| | **Fourth Quarter** | **Fourth Quarter** | **Fourth Quarter** | **Full Year** | **Full Year** | **Full Year** |
|  | **2022** | **2021** | **Change** | **2022** | **2021** | **Change** |
| **Net revenues** | $**5456** | $**5591** | **(2.4)%** | $**22476** | $**22866** | **(1.7)%** |
| Excise taxes | (1000) | (1134) |  | (4289) | (4754) |  |
| **Revenues net of excise taxes** | $**4456** | $**4457** | **— %** | $**18187** | $**18112** | **0.4%** |
| **Reported OCI** | $**2576** | $**2493** | **3.3%** | $**10688** | $**10394** | **2.8%** |
| NPM Adjustment Items | (3) |  |  | (63) | (53) |  |
| Tobacco and health and certain other litigation items | 30 | 11 |  | 101 | 83 |  |
| **Adjusted OCI** | $**2603** | $**2504** | **4.0%** | $**10726** | $**10424** | **2.9%** |
| **Adjusted OCI margins** <sup>1</sup> | **58.4%** | **56.2%** | **2.2 pp** | **59.0%** | **57.6%** | **1.4 pp** |

---

<sup>1</sup> *Adjusted OCI margins are calculated as adjusted OCI divided by revenues net of excise taxes.*

**Shipment Volume**

**Fourth Quarter** 

***•*** Smokeable products segment reported domestic cigarette shipment volume decreased 12.1%, primarily driven by the industry's decline rate and retail share losses (both of which were impacted by macroeconomic pressures on ATC disposable income) and calendar differences.

***•*** When adjusted for calendar differences, smokeable products segment domestic cigarette shipment volume decreased by an estimated 11%.

***•*** When adjusted for trade inventory movements, calendar differences and other factors, total estimated domestic cigarette industry volume decreased by an estimated 9%.

***•*** Reported cigar shipment volume decreased 3.8%, primarily driven by macroeconomic pressures on ATC disposable income, trade inventory movements and other factors.

**Full Year**

***•*** Smokeable products segment reported domestic cigarette shipment volume decreased 9.7%, primarily driven by the industry's decline rate and retail share losses (both of which were impacted by macroeconomic

------

pressures on ATC disposable income) and calendar differences, partially offset by trade inventory movements.

***•*** When adjusted for calendar differences and trade inventory movements, smokeable products segment domestic cigarette shipment volume decreased by an estimated 9.5%.

***•*** When adjusted for trade inventory movements, calendar differences and other factors, total estimated domestic cigarette industry volume decreased by an estimated 8%.

***•*** Reported cigar shipment volume decreased 4.0%, primarily driven by macroeconomic pressures on ATC disposable income, trade inventory movements and other factors.

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **Table 3 - Smokeable Products: Reported Shipment Volume (sticks in millions)** | **Table 3 - Smokeable Products: Reported Shipment Volume (sticks in millions)** | **Table 3 - Smokeable Products: Reported Shipment Volume (sticks in millions)** | **Table 3 - Smokeable Products: Reported Shipment Volume (sticks in millions)** | **Table 3 - Smokeable Products: Reported Shipment Volume (sticks in millions)** | **Table 3 - Smokeable Products: Reported Shipment Volume (sticks in millions)** | **Table 3 - Smokeable Products: Reported Shipment Volume (sticks in millions)** |
| | **Fourth Quarter** | **Fourth Quarter** | **Fourth Quarter** | **Full Year** | **Full Year** | **Full Year** |
|  | **2022** | **2021** | **Change** | **2022** | **2021** | **Change** |
| **Cigarettes:** |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;***Marlboro*** | 17597 | 19848 | (11.3)% | 75406 | 82970 | (9.1)% |
| &nbsp;&nbsp;&nbsp;&nbsp;**Other premium** | 915 | 1036 | (11.7)% | 3866 | 4216 | (8.3)% |
| &nbsp;&nbsp;&nbsp;&nbsp;**Discount** | 1195 | 1539 | (22.4)% | 5406 | 6607 | (18.2)% |
| **Total cigarettes** | **19707** | **22423** | **(12.1)%** | **84678** | **93793** | **(9.7)%** |
| **Cigars:** |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;***Black & Mild*** | 424 | 440 | (3.6)% | 1727 | 1796 | (3.8)% |
| &nbsp;&nbsp;&nbsp;&nbsp;**Other** | 1 | 2 | (50.0)% | 4 | 7 | (42.9)% |
| **Total cigars** | **425** | **442** | **(3.8)%** | **1731** | **1803** | **(4.0)%** |
| **Total smokeable products** | **20132** | **22865** | **(12.0)%** | **86409** | **95596** | **(9.6)%** |

---

*Note: Cigarettes volume includes units sold as well as promotional units but excludes units sold for distribution to Puerto Rico, U.S. Territories to overseas military and by Philip Morris Duty Free Inc., none of which, individually or in the aggregate, is material to our smokeable products segment.*

**Retail Share and Brand Activity**

 **Fourth Quarter**

***•*** *Marlboro* retail share of the total cigarette category was 42.2%, a decrease of 0.4 share points, primarily due to increased macroeconomic pressures on ATC disposable income and increased competitive activity. However, *Marlboro* share of the premium segment was 58.4%, an increase of 0.7 share points versus the prior year and was flat sequentially.

***•*** The cigarette industry discount retail share increased 1.7 share points to 27.8%, primarily due to the ATC factors mentioned above.

**Full Year**

***•*** *Marlboro* retail share of the total cigarette category was 42.5%, a decrease of 0.4 share points, primarily due to increased macroeconomic pressures on ATC disposable income and increased competitive activity. However, *Marlboro* share of the premium segment grew to 58.2%, an increase of 0.5 share points.

***•*** The cigarette industry discount retail share increased 1.4 share points to 26.9%, primarily due to the ATC factors mentioned above.

------

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **Table 4 - Smokeable Products: Cigarettes Retail Share (percent)** | **Table 4 - Smokeable Products: Cigarettes Retail Share (percent)** | **Table 4 - Smokeable Products: Cigarettes Retail Share (percent)** | **Table 4 - Smokeable Products: Cigarettes Retail Share (percent)** | | | |
| | **Fourth Quarter** | **Fourth Quarter** | **Fourth Quarter** | **Full Year** | **Full Year** | **Full Year** |
|  | **2022** | **2021** | **Percentage point change** | **2022** | **2021** | **Percentage point change** |
| **Cigarettes:** |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;***Marlboro*** | 42.2% | 42.6% | (0.4) | 42.5% | 42.9% | (0.4) |
| &nbsp;&nbsp;&nbsp;&nbsp;**Other premium** | 2.3 | 2.3 |  | 2.3 | 2.3 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;**Discount** | 2.9 | 3.3 | (0.4) | 3.1 | 3.5 | (0.4) |
| **Total cigarettes** | **47.4%** | **48.2%** | **(0.8)** | **47.9%** | **48.7%** | **(0.8)** |

---

*Note: Retail share results for cigarettes are based on data from IRI/MSAi, a tracking service that uses a sample of stores and certain wholesale shipments to project market share and depict share trends. This service tracks sales in the food, drug, mass merchandisers, convenience, military, dollar store and club trade classes. For other trade classes selling cigarettes, retail share is based on shipments from wholesalers to retailers (STARS). This service is not designed to capture sales through other channels, including the internet, direct mail and some illicitly tax-advantaged outlets. It is IRI's standard practice to periodically refresh its services, which could restate retail share results that were previously released in this service.*

------

**ORAL TOBACCO PRODUCTS**

**Revenues and OCI**

**Fourth Quarter**

***•*** Net revenues decreased 4.7%, primarily driven by higher promotional investments in *on!*, lower shipment volume and a higher percentage of *on!* shipment volume relative to MST versus the prior year (mix change), partially offset by higher pricing. Revenues net of excise taxes decreased 4.0%.

***•*** Reported and adjusted OCI decreased 5.1%, primarily driven by higher promotional investments in *on!*, lower shipment volume and mix change, partially offset by higher pricing. Adjusted OCI margins declined by 0.7 percentage points to 61.3%.

**Full Year**

***•*** Net revenues decreased 1.1%, primarily driven by higher promotional investments in *on!*, lower shipment volume and mix change, partially offset by higher pricing. Revenues net of excise taxes decreased 0.6%.

***•*** Reported OCI decreased 1.6%, primarily driven by higher promotional investments in *on!*, lower shipment volume, mix change and higher costs, partially offset by higher pricing and 2021 acquisition-related costs.

***•*** Adjusted OCI decreased 3.8%, primarily driven by higher promotional investments in *on!*, lower shipment volume, mix change and higher costs, partially offset by higher pricing. Adjusted OCI margins declined by 2.2 percentage points to 66.3%.

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **Table 5 - Oral Tobacco Products: Revenues and OCI ($ in millions)** | **Table 5 - Oral Tobacco Products: Revenues and OCI ($ in millions)** | **Table 5 - Oral Tobacco Products: Revenues and OCI ($ in millions)** | **Table 5 - Oral Tobacco Products: Revenues and OCI ($ in millions)** | | | |
| | **Fourth Quarter** | **Fourth Quarter** | **Fourth Quarter** | **Full Year** | **Full Year** | **Full Year** |
|  | **2022** | **2021** | **Change** | **2022** | **2021** | **Change** |
| **Net revenues** | $**632** | $**663** | **(4.7)%** | $**2580** | $**2608** | **(1.1)%** |
| Excise taxes | (28) | (34) |  | (119) | (132) |  |
| **Revenues net of excise taxes** | $**604** | $**629** | **(4.0)%** | $**2461** | $**2476** | **(0.6)%** |
| **Reported OCI** | $**370** | $**390** | **(5.1)%** | $**1632** | $**1659** | **(1.6)%** |
| Asset impairment, exit, implementation, acquisition and disposition-related costs |  |  |  |  | 37 |  |
| **Adjusted OCI** | $**370** | $**390** | **(5.1)%** | $**1632** | $**1696** | **(3.8)%** |
| **Adjusted OCI margins** <sup>1</sup> | **61.3%** | **62.0%** | **(0.7) pp** | **66.3%** | **68.5%** | **(2.2) pp** |

---

<sup>1</sup> *Adjusted OCI margins are calculated as adjusted OCI divided by revenues net of excise taxes.*

**Shipment Volume**

**Fourth Quarter**

***•*** Oral tobacco products segment reported domestic shipment volume decreased 4.3%, primarily driven by retail share losses, calendar differences and other factors, partially offset by the industry's growth rate and trade inventory movements. When adjusted for calendar differences and trade inventory movements, oral tobacco products segment shipment volume decreased by an estimated 3.5%.

**Full Year** 

***•*** Oral tobacco products segment reported domestic shipment volume decreased 2.4%, primarily driven by retail share losses, trade inventory movements and calendar differences, partially offset by the industry's growth rate and other factors. When adjusted for trade inventory movements and calendar differences, oral tobacco products segment shipment volume decreased by an estimated 2%.

***•*** Total oral tobacco industry volume increased by an estimated 1% for the six months ended December 31, 2022, primarily driven by growth in oral nicotine pouches, partially offset by declines in MST volumes (which includes the impact of macroeconomic pressures on ATC disposable income).&nbsp;&nbsp;&nbsp;&nbsp;

------

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **Table 6 - Oral Tobacco Products: Reported Shipment Volume (cans and packs in millions)** | **Table 6 - Oral Tobacco Products: Reported Shipment Volume (cans and packs in millions)** | **Table 6 - Oral Tobacco Products: Reported Shipment Volume (cans and packs in millions)** | **Table 6 - Oral Tobacco Products: Reported Shipment Volume (cans and packs in millions)** | **Table 6 - Oral Tobacco Products: Reported Shipment Volume (cans and packs in millions)** | **Table 6 - Oral Tobacco Products: Reported Shipment Volume (cans and packs in millions)** | **Table 6 - Oral Tobacco Products: Reported Shipment Volume (cans and packs in millions)** |
| | **Fourth Quarter** | **Fourth Quarter** | **Fourth Quarter** | **Full Year** | **Full Year** | **Full Year** |
|  | **2022** | **2021** | **Change** | **2022** | **2021** | **Change** |
| ***Copenhagen*** | 114.1 | 125.2 | (8.9)% | 470.6 | 503.6 | (6.6)% |
| ***Skoal*** | 43.3 | 49.2 | (12.0)% | 179.4 | 197.4 | (9.1)% |
| ***on!*** | 22.9 | 13.8 | 65.9% | 82.5 | 48.4 | 70.5% |
| **Other** | 16.8 | 17.8 | (5.6)% | 68.1 | 70.9 | (3.9)% |
| **Total oral tobacco products** | **197.1** | **206.0** | **(4.3)%** | **800.6** | **820.3** | **(2.4)%** |

---

*Note: Volume includes cans and packs sold, as well as promotional units, but excludes international volume, which is currently not material to our oral tobacco products segment. New types of oral tobacco products, as well as new packaging configurations of existing oral tobacco products, may or may not be equivalent to existing MST products on a can-for-can basis. To calculate volumes of cans and packs shipped, one pack of snus or one can of oral nicotine pouches, irrespective of the number of pouches in the pack, is assumed to be equivalent to one can of MST.*

**Retail Share and Brand Activity**

**Fourth Quarter**

***•*** Oral tobacco products segment retail share was 45.9%, and *Copenhagen* continued to be the leading oral tobacco brand with a retail share of 26.1%. In the oral tobacco products segment, share declines for MST products were primarily driven by the share growth of oral nicotine pouches.

***•*** Total U.S. oral tobacco category share for *on!* nicotine pouches grew to 5.9%, an increase of 2.1 percentage points.

• The U.S. nicotine pouch category grew to 24.4% of the U.S. oral tobacco category, an increase of 6.5 share points versus the prior year. In addition, *on!* share of the nicotine pouch category grew to 24.0%, an increase of 2.5 share points versus the prior year.

**Full Year**

***•*** Oral tobacco products segment retail share was 46.4%, and *Copenhagen* continued to be the leading oral tobacco brand with a retail share of 27.0%. In the oral tobacco products segment, share declines for MST products were primarily driven by the share growth of oral nicotine pouches.

***•*** Total U.S. oral tobacco category share for *on!* nicotine pouches grew to 5.0%, an increase of 2.4 percentage points.

• The U.S. nicotine pouch category grew to 21.9% of the U.S. oral tobacco category, an increase of 6.5 share points versus the prior year. In addition, *on!* share of the nicotine pouch category grew to 23.0%, an increase of 6.1 share points versus the prior year.

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **Table 7 - Oral Tobacco Products: Retail Share (percent)** | **Table 7 - Oral Tobacco Products: Retail Share (percent)** | **Table 7 - Oral Tobacco Products: Retail Share (percent)** | **Table 7 - Oral Tobacco Products: Retail Share (percent)** | **Table 7 - Oral Tobacco Products: Retail Share (percent)** | **Table 7 - Oral Tobacco Products: Retail Share (percent)** | **Table 7 - Oral Tobacco Products: Retail Share (percent)** |
| | **Fourth Quarter** | **Fourth Quarter** | **Fourth Quarter** | **Full Year** | **Full Year** | **Full Year** |
|  | **2022** | **2021** | **Percentage point change** | **2022** | **2021** | **Percentage point change** |
| ***Copenhagen*** | 26.1% | 28.6% | (2.5) | 27.0% | 29.5% | (2.5) |
| ***Skoal*** | 10.8 | 12.0 | (1.2) | 11.3 | 12.5 | (1.2) |
| ***on!*** | 5.9 | 3.8 | 2.1 | 5.0 | 2.6 | 2.4 |
| **Other** | 3.1 | 3.2 | (0.1) | 3.1 | 3.1 |  |
| **Total oral tobacco products** | **45.9%** | **47.6%** | **(1.7)** | **46.4%** | **47.7%** | **(1.3)** |

---

*Note: The oral tobacco products retail share results exclude international volume. Retail share results for oral tobacco products are based on data from IRI InfoScan, a tracking service that uses a sample of stores to project market share and depict share trends. This service tracks sales in the food, drug, mass merchandisers, convenience, military, dollar store and club trade classes on the number of cans and packs sold. Oral tobacco products is defined by IRI as moist smokeless, snus and oral nicotine pouches. New types of oral tobacco products, as well as new packaging configurations of existing oral tobacco products, may or may not be equivalent to existing MST products on a can-for-can basis. For example, one pack of snus or one can of oral nicotine pouches, irrespective of the number of pouches in the pack, is assumed to be equivalent to one can of MST. Because this service represents retail share performance only in key trade channels, it should not be considered a precise measurement of actual retail share. It is IRI's standard practice to periodically refresh its InfoScan services, which could restate retail share results that were previously released in this service.*

------

**Altria's Profile**

We have a leading portfolio of tobacco products for U.S. tobacco consumers age 21+. Our Vision by 2030 is to responsibly lead the transition of adult smokers to a smoke-free future (Vision). We are *Moving Beyond Smoking*™, leading the way in moving adult smokers away from cigarettes by taking action to transition millions to potentially less harmful choices - believing it is a substantial opportunity for adult tobacco consumers, our businesses and society.

Our wholly owned subsidiaries include leading manufacturers of both combustible and smoke-free products. In combustibles, we own Philip Morris USA Inc. (PM USA), the most profitable U.S. cigarette manufacturer, and John Middleton Co. (Middleton), a leading U.S. cigar manufacturer. Our smoke-free portfolio includes ownership of U.S. Smokeless Tobacco Company LLC (USSTC), the leading global moist smokeless tobacco (MST) manufacturer, and Helix Innovations LLC (Helix), a leading manufacturer of oral nicotine pouches.

Additionally, we have a majority-owned joint venture, Horizon Innovations LLC (Horizon), for the U.S. marketing and commercialization of heated tobacco stick products and, through a separate agreement, we have the exclusive U.S. commercialization rights to the *IQOS Tobacco Heating System*® and *Marlboro HeatSticks*® through April 2024.

Our equity investments include Anheuser-Busch InBev SA/NV (ABI), the world's largest brewer, Cronos Group Inc. (Cronos), a leading Canadian cannabinoid company, and JUUL Labs, Inc. (JUUL), a U.S. based e-vapor company.

The brand portfolios of our tobacco operating companies include *Marlboro*®, *Black & Mild*®, *Copenhagen*®, *Skoal*® and *on!*®. Trademarks and service marks related to Altria referenced in this release are the property of Altria or our subsidiaries or are used with permission.

Learn more about Altria at <u>www.altria.com</u> and follow us on Twitter, Facebook and LinkedIn.

**Basis of Presentation**

We report our financial results in accordance with GAAP. Our management reviews OCI, which is defined as operating income before general corporate expenses and amortization of intangibles, to evaluate the performance of, and allocate resources to, our segments. Our management also reviews certain financial results, including OCI, OCI margins and diluted EPS, on an adjusted basis, which excludes certain income and expense items, including those items noted under "2023 Full-Year Guidance." Our management does not view any of these special items to be part of our underlying results as they may be highly variable, may be unusual or infrequent, are difficult to predict and can distort underlying business trends and results. Our management also reviews income tax rates on an adjusted basis. Our adjusted effective tax rate may exclude certain income tax items from our reported effective tax rate. Our management believes that adjusted financial measures provide useful additional insight into underlying business trends and results, and provide a more meaningful comparison of year-over-year results. Our management uses adjusted financial measures for planning, forecasting and evaluating business and financial performance, including allocating resources and evaluating results relative to employee compensation targets. These adjusted financial measures are not required by, or calculated in accordance with GAAP and may not be calculated the same as similarly titled measures used by other companies. These adjusted financial measures should thus be considered as supplemental in nature and not considered in isolation or as a substitute for the related financial information prepared in accordance with GAAP. We provide reconciliations of historical adjusted financial measures to corresponding GAAP measures in this release.

We use the equity method of accounting for our investment in ABI and Cronos and report our share of ABI's and Cronos's results using a one-quarter lag because ABI's and Cronos's results are not available in time for us to record them in the concurrent period. The one-quarter reporting lag for ABI and Cronos does not affect our cash flows. We account for our investment in the equity securities of JUUL at fair value.

Our reportable segments are (i) smokeable products, including combustible cigarettes and cigars manufactured and sold by PM USA and Middleton, respectively, and (ii) oral tobacco products, including MST and snus products manufactured and sold by USSTC, and oral nicotine pouches sold by Helix. Prior to the sale of Ste.

------

Michelle Wine Estates Ltd. (Ste. Michelle) on October 1, 2021, wine produced and/or sold by Ste. Michelle was a reportable segment. We have included results for PMCC, the *IQOS Tobacco Heating System*® and Helix rest-of-world in "All Other." Comparisons are to the corresponding prior-year period unless otherwise stated.

**Forward-Looking and Cautionary Statements**

This release contains projections of future results and other forward-looking statements that are subject to a number of risks and uncertainties and are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995.

Important factors that may cause actual results to differ materially from those contained in the forward-looking statements included in this release are described in our publicly filed reports, including our Annual Report on Form 10-K for the year ended December 31, 2021 and our 2022 Quarterly Reports on Form 10-Q. These factors include the following:

&nbsp;&nbsp;&nbsp;&nbsp;▪ unfavorable litigation outcomes, including risks associated with adverse jury and judicial determinations, courts and arbitrators reaching conclusions at variance with our or any of our investees' understanding of applicable law, bonding requirements in the jurisdictions that do not limit the dollar amount of appeal bonds and certain challenges to bond cap statutes;

&nbsp;&nbsp;&nbsp;&nbsp;▪ government (including the U.S. Food and Drug Administration (FDA)) and private sector actions that impact adult tobacco consumer acceptability of, or access to, tobacco products;

&nbsp;&nbsp;&nbsp;&nbsp;▪ tobacco product taxation, including lower tobacco product consumption levels and potential shifts in adult tobacco consumer purchases as a result of federal, state and local excise tax increases, and excise taxes on e-vapor and oral nicotine products and the impact on adult tobacco consumers' transition to lower priced tobacco products;

&nbsp;&nbsp;&nbsp;&nbsp;▪ unfavorable outcomes of any government investigations of us or our investees;

&nbsp;&nbsp;&nbsp;&nbsp;▪ a successful challenge to our tax positions, an increase to the corporate income tax rate or other changes to federal or state tax laws;

&nbsp;&nbsp;&nbsp;&nbsp;▪ the risks related to our and our investees' international business operations, including failure to prevent violations of various United States and foreign laws and regulations such as foreign privacy laws and laws prohibiting bribery and corruption;

&nbsp;&nbsp;&nbsp;&nbsp;▪ the risks associated with health epidemics and pandemics, including the COVID-19 pandemic and similar outbreaks, such as their impact on our and our investees' ability to continue manufacturing and distributing products (directly or indirectly due to their impact on suppliers, distributors and distribution chain service providers) and their impact on macroeconomic conditions and, in turn, adult tobacco consumer purchasing behavior;

&nbsp;&nbsp;&nbsp;&nbsp;▪ the failure of our and our investees' efforts to compete effectively in their respective markets;

&nbsp;&nbsp;&nbsp;&nbsp;▪ the growth of the e-vapor category and other innovative tobacco products, including oral nicotine pouches, contributing to reductions in cigarette and MST consumption levels and sales volume;

&nbsp;&nbsp;&nbsp;&nbsp;▪ our ability to promote brand equity successfully; anticipate and respond to evolving adult tobacco consumer preferences; develop, manufacture, market and distribute products that appeal to adult tobacco consumers; promote productivity; and protect or enhance margins through cost savings and price increases;

&nbsp;&nbsp;&nbsp;&nbsp;▪ our failure to develop and commercialize innovative products, including innovative tobacco products that may reduce the health risks associated with cigarettes and other traditional tobacco products, that appeal to adult tobacco consumers;

&nbsp;&nbsp;&nbsp;&nbsp;▪ changes, including in macroeconomic and geopolitical conditions (including inflation), that result in shifts in adult tobacco consumer disposable income and purchasing behavior, including choosing lower-priced and discount brands;

&nbsp;&nbsp;&nbsp;&nbsp;▪ significant changes in price, availability or quality of tobacco, other raw materials or component parts, including as a result of changes in macroeconomic, climate and geopolitical conditions, including the Russian invasion of Ukraine;

------

&nbsp;&nbsp;&nbsp;&nbsp;▪ the risks, including FDA regulatory risks, related to our and our investees' reliance on a few significant facilities and a small number of key suppliers, distributors and distribution chain service providers, and the risk of an extended disruption at a facility of, or of service by, a supplier, distributor or distribution chain service provider of our tobacco subsidiaries or our investees;

&nbsp;&nbsp;&nbsp;&nbsp;▪ required or voluntary product recalls or prohibition on the marketing or sale of our or any of our investees' products as a result of various circumstances such as FDA or other regulatory action or product contamination;

&nbsp;&nbsp;&nbsp;&nbsp;▪ the failure of our information systems or the information systems of key suppliers or service providers to function as intended, or cyber attacks or security breaches;

&nbsp;&nbsp;&nbsp;&nbsp;▪ our inability to attract and retain the best talent due to the impact of decreasing social acceptance of tobacco usage, tobacco control actions and other factors, including current labor market dynamics;

&nbsp;&nbsp;&nbsp;&nbsp;▪ impairment losses as a result of the write down of intangible assets, including goodwill;

&nbsp;&nbsp;&nbsp;&nbsp;▪ the adverse effect of acquisitions, investments, dispositions or other events on our credit rating;

&nbsp;&nbsp;&nbsp;&nbsp;▪ our inability to acquire attractive businesses or make attractive investments on favorable terms, or at all, or to realize the anticipated benefits from an acquisition or investment and our inability to dispose of businesses or investments on favorable terms or at all;

&nbsp;&nbsp;&nbsp;&nbsp;▪ the risks related to disruption and uncertainty in the credit and capital markets, including risk of losing access to these markets, which may adversely affect our earnings or dividend rate or both;

&nbsp;&nbsp;&nbsp;&nbsp;▪ our inability to attract and retain investors due to the impact of decreasing social acceptance of tobacco usage or unfavorable ESG ratings;

&nbsp;&nbsp;&nbsp;&nbsp;▪ the risk that any challenge to our investment in JUUL, if successful, could result in a broad range of resolutions, including divestiture of the investment or rescission of the transaction;

&nbsp;&nbsp;&nbsp;&nbsp;▪ the risks generally related to our investments in JUUL and Cronos, including our inability to realize the expected benefits of our investments in the expected time frames, or at all, due to the risks encountered by our investees in their businesses, such as operational, competitive, compliance, litigation and reputational risks, and legislative and regulatory risks at the international, federal, state and local levels; and changes in the fair value of our investment in JUUL and impairment of our investment in Cronos;

&nbsp;&nbsp;&nbsp;&nbsp;▪ the risks related to our inability to acquire a controlling interest in JUUL as a result of standstill restrictions or to control the material decisions of JUUL and restrictions on our ability to sell or otherwise transfer our shares of JUUL until December 20, 2024;

&nbsp;&nbsp;&nbsp;&nbsp;▪ the risks associated with our investment in ABI, including effects of the COVID-19 pandemic, foreign currency exchange rates and macroeconomic and geopolitical conditions, including the Russian invasion of Ukraine, on ABI's business and the impact on our earnings from, and carrying value of, our investment in ABI;

&nbsp;&nbsp;&nbsp;&nbsp;▪ the risks related to our ownership percentage in ABI decreasing below certain levels, including additional tax liabilities, a reduction in the number of directors that we have the right to have appointed to the ABI board of directors and our potential inability to use the equity method of accounting for our investment in ABI;

&nbsp;&nbsp;&nbsp;&nbsp;▪ the risk of a successful challenge to the tax treatment of our equity investment in ABI; and

&nbsp;&nbsp;&nbsp;&nbsp;▪ the risks, including criminal, civil or tax liability, related to our or Cronos's failure to comply with applicable laws, including cannabis laws.

You should understand that it is not possible to predict or identify all factors and risks. Consequently, you should not consider the foregoing list complete. We do not undertake to update any forward-looking statement that we may make from time to time except as required by applicable law. All subsequent written and oral forward-looking statements attributable to Altria or any person acting on our behalf are expressly qualified in their entirety by the cautionary statements referenced above.

---

| | | |
|:---|:---|:---|
| Source: Altria Group, Inc. | Altria Client Services | Altria Client Services |
| Mac Livingston, Vice President of Investor Relations | Investor Relations | Media Relations |
| Richard.M.Livingston@altria.com | 804-484-8222 | 804-484-8897 |

---

------

---

| |
|:---|
| Schedule 1 |
| ALTRIA GROUP, INC. |
| and Subsidiaries |
| Consolidated Statements of Earnings |
| For the Quarters Ended December 31,  |
| (dollars in millions, except per share data) |
| (Unaudited) |

---

---

| | | | |
|:---|:---|:---|:---|
| | **2022** | **2021** | **% Change** |
| **Net revenues** | $**6111** | $**6255** | **(2.3)%** |
| Cost of sales <sup>1</sup> | 1573 | 1771 |  |
| Excise taxes on products <sup>1</sup> | 1028 | 1169 |  |
| Gross profit | 3510 | 3315 | 5.9% |
| Marketing, administration and research costs | 573 | 473 |  |
| **Operating companies income**  | **2937** | **2842** | **3.3%** |
| Amortization of intangibles | 19 | 19 |  |
| General corporate expenses | 100 | 90 |  |
| **Operating income**  | **2818** | **2733** | **3.1%** |
| Interest and other debt expense, net | 226 | 293 |  |
| Net periodic benefit income, excluding service cost | (47) | (50) |  |
| (Income) losses from investments in equity securities <sup>1</sup> | (66) | 190 |  |
| Loss on Cronos-related financial instruments | 1 | 20 |  |
| Earnings before income taxes | 2704 | 2280 | **18.6%** |
| Provision for income taxes | 14 | 656 |  |
| **Net earnings attributable to Altria** | $**2690** | $**1624** | **65.6%** |
| **Per share data:** |  |  |  |
| **Diluted earnings per share attributable to Altria** | $**1.50** | $**0.88** | **70.5%** |
| Weighted-average diluted shares outstanding | 1790 | 1832 | (2.3)% |
| <sup>1</sup> Cost of sales includes charges for resolution expenses related to state settlement agreements and FDA user fees. Supplemental information concerning those items, excise taxes on products sold and (income) losses from investments in equity securities is shown in Schedule 5. | <sup>1</sup> Cost of sales includes charges for resolution expenses related to state settlement agreements and FDA user fees. Supplemental information concerning those items, excise taxes on products sold and (income) losses from investments in equity securities is shown in Schedule 5. | <sup>1</sup> Cost of sales includes charges for resolution expenses related to state settlement agreements and FDA user fees. Supplemental information concerning those items, excise taxes on products sold and (income) losses from investments in equity securities is shown in Schedule 5. | <sup>1</sup> Cost of sales includes charges for resolution expenses related to state settlement agreements and FDA user fees. Supplemental information concerning those items, excise taxes on products sold and (income) losses from investments in equity securities is shown in Schedule 5. |

---

------

---

| | | | | |
|:---|:---|:---|:---|:---|
| | | | | Schedule 2 |
| ALTRIA GROUP, INC. | ALTRIA GROUP, INC. | ALTRIA GROUP, INC. | ALTRIA GROUP, INC. | ALTRIA GROUP, INC. |
| and Subsidiaries | and Subsidiaries | and Subsidiaries | and Subsidiaries | and Subsidiaries |
| Selected Financial Data | Selected Financial Data | Selected Financial Data | Selected Financial Data | Selected Financial Data |
| For the Quarters Ended December 31,  | For the Quarters Ended December 31,  | For the Quarters Ended December 31,  | For the Quarters Ended December 31,  | For the Quarters Ended December 31,  |
| (dollars in millions) | (dollars in millions) | (dollars in millions) | (dollars in millions) | (dollars in millions) |
| (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) |
|  | **Net Revenues** | **Net Revenues** | **Net Revenues** | **Net Revenues** |
|  | **Smokeable Products** | **Oral Tobacco Products** | **All Other** | **Total** |
| 2022 | $5456 | $632 | $23 | $6111 |
| 2021 | 5591 | 663 | 1 | 6255 |
| % Change | (2.4)% | (4.7)% | 100%+ | (2.3)% |
| **<u>Reconciliation:</u>** |  |  |  |  |
| **For the quarter ended December 31, 2021** | $**5591** | $**663** | $**1** | $**6255** |
| Operations | (135) | (31) | 22 | (144) |
| **For the quarter ended December 31, 2022** | $**5456** | $**632** | $**23** | $**6111** |
|  | **Operating Companies Income (Loss)** | **Operating Companies Income (Loss)** | **Operating Companies Income (Loss)** | **Operating Companies Income (Loss)** |
|  | **Smokeable Products** | **Oral Tobacco Products** | **All Other** | **Total** |
| 2022 | $2576 | $370 | $(9) | $2937 |
| 2021 | 2493 | 390 | (41) | 2842 |
| % Change | 3.3% | (5.1)% | 78.0% | 3.3% |
| **<u>Reconciliation:</u>** |  |  |  |  |
| **For the quarter ended December 31, 2021** | $**2493** | $**390** | $**(41)** | $**2842** |
| Tobacco and health and certain other litigation items - 2021 | 11 |  |  | 11 |
|  | 11 |  |  | 11 |
| NPM Adjustment Items - 2022 | 3 |  |  | 3 |
| Tobacco and health and certain other litigation items - 2022 | (30) |  |  | (30) |
|  | (27) |  |  | (27) |
| Operations | 99 | (20) | 32 | 111 |
| **For the quarter ended December 31, 2022** | $**2576** | $**370** | $**(9)** | $**2937** |

---

------

---

| | | | |
|:---|:---|:---|:---|
| | | | Schedule 3 |
| ALTRIA GROUP, INC. | ALTRIA GROUP, INC. | ALTRIA GROUP, INC. | ALTRIA GROUP, INC. |
| and Subsidiaries | and Subsidiaries | and Subsidiaries | and Subsidiaries |
| Consolidated Statements of Earnings | Consolidated Statements of Earnings | Consolidated Statements of Earnings | Consolidated Statements of Earnings |
| For the Years Ended December 31, | For the Years Ended December 31, | For the Years Ended December 31, | For the Years Ended December 31, |
| (dollars in millions, except per share data) | (dollars in millions, except per share data) | (dollars in millions, except per share data) | (dollars in millions, except per share data) |
| (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) |
|  | **2022** | **2021** | **% Change** |
| **Net revenues** | $**25096** | $**26013** | **(3.5)%** |
| Cost of sales <sup>1</sup> | 6442 | 7119 |  |
| Excise taxes on products <sup>1</sup> | 4408 | 4902 |  |
| Gross profit | 14246 | 13992 | 1.8% |
| Marketing, administration and research costs | 1962 | 2015 |  |
| **Operating companies income** | **12284** | **11977** | **2.6%** |
| Amortization of intangibles | 73 | 72 |  |
| General corporate expenses | 292 | 345 |  |
| **Operating income** | **11919** | **11560** | **3.1%** |
| Interest and other debt expense, net | 1058 | 1162 |  |
| Loss on early extinguishment of debt |  | 649 |  |
| Net periodic benefit income, excluding service cost | (184) | (202) |  |
| (Income) losses from investments in equity securities <sup>1</sup>  | 3641 | 5979 |  |
| Loss on Cronos-related financial instruments | 15 | 148 |  |
| Earnings before income taxes | 7389 | 3824 | 93.2% |
| Provision for income taxes | 1625 | 1349 |  |
| **Net earnings attributable to Altria** | $**5764** | $**2475** | **100%+** |
| **Per share data**<sup>2</sup>**:** |  |  |  |
| **Diluted earnings per share attributable to Altria** | $**3.19** | $**1.34** | **100%+** |
| Weighted-average diluted shares outstanding | 1804 | 1845 | (2.2)% |
| <sup>1</sup> Cost of sales includes charges for resolution expenses related to state settlement agreements and FDA user fees. Supplemental information concerning those items, excise taxes on products sold and (income) losses from investments in equity securities is shown in Schedule 5. | <sup>1</sup> Cost of sales includes charges for resolution expenses related to state settlement agreements and FDA user fees. Supplemental information concerning those items, excise taxes on products sold and (income) losses from investments in equity securities is shown in Schedule 5. | <sup>1</sup> Cost of sales includes charges for resolution expenses related to state settlement agreements and FDA user fees. Supplemental information concerning those items, excise taxes on products sold and (income) losses from investments in equity securities is shown in Schedule 5. | <sup>1</sup> Cost of sales includes charges for resolution expenses related to state settlement agreements and FDA user fees. Supplemental information concerning those items, excise taxes on products sold and (income) losses from investments in equity securities is shown in Schedule 5. |
| <sup>2</sup> Diluted earnings per share attributable to Altria are computed independently for each period. Accordingly, the sum of the quarterly earnings per share amounts may not agree to the year-to-date amounts.  | <sup>2</sup> Diluted earnings per share attributable to Altria are computed independently for each period. Accordingly, the sum of the quarterly earnings per share amounts may not agree to the year-to-date amounts.  | <sup>2</sup> Diluted earnings per share attributable to Altria are computed independently for each period. Accordingly, the sum of the quarterly earnings per share amounts may not agree to the year-to-date amounts.  | <sup>2</sup> Diluted earnings per share attributable to Altria are computed independently for each period. Accordingly, the sum of the quarterly earnings per share amounts may not agree to the year-to-date amounts.  |

---

------

&nbsp;&nbsp;&nbsp;&nbsp;

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | | | | | Schedule 4 |
| ALTRIA GROUP, INC. | ALTRIA GROUP, INC. | ALTRIA GROUP, INC. | ALTRIA GROUP, INC. | ALTRIA GROUP, INC. | ALTRIA GROUP, INC. |
| and Subsidiaries | and Subsidiaries | and Subsidiaries | and Subsidiaries | and Subsidiaries | and Subsidiaries |
| Selected Financial Data | Selected Financial Data | Selected Financial Data | Selected Financial Data | Selected Financial Data | Selected Financial Data |
| For the Years Ended December 31, | For the Years Ended December 31, | For the Years Ended December 31, | For the Years Ended December 31, | For the Years Ended December 31, | For the Years Ended December 31, |
| (dollars in millions) | (dollars in millions) | (dollars in millions) | (dollars in millions) | (dollars in millions) | (dollars in millions) |
| (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) |
|  | **Net Revenues** | **Net Revenues** | **Net Revenues** | **Net Revenues** | **Net Revenues** |
|  | **Smokeable Products** | **Oral Tobacco Products** | **Wine** | **All Other** | **Total** |
| 2022 | $22476 | $2580 | $— | $40 | $25096 |
| 2021 | 22866 | 2608 | 494 | 45 | 26013 |
| % Change | (1.7)% | (1.1)% | (100.0)% | (11.1)% | (3.5)% |
| **<u>Reconciliation:</u>** |  |  |  |  |  |
| **For the year ended December 31, 2021** | $**22866** | $**2608** | $**494** | $**45** | $**26013** |
| Operations | (390) | (28) | (494) | (5) | (917) |
| **For the year ended December 31, 2022** | $**22476** | $**2580** | $**—** | $**40** | $**25096** |
|  | **Operating Companies Income (Loss)** | **Operating Companies Income (Loss)** | **Operating Companies Income (Loss)** | **Operating Companies Income (Loss)** | **Operating Companies Income (Loss)** |
|  | **Smokeable Products** | **Oral Tobacco Products** | **Wine** | **All Other** | **Total** |
| 2022 | $10688 | $1632 | $— | $(36) | $12284 |
| 2021 | 10394 | 1659 | 21 | (97) | 11977 |
| % Change | 2.8% | (1.6)% | (100.0)% | 62.9% | 2.6% |
| **<u>Reconciliation:</u>** |  |  |  |  |  |
| **For the year ended December 31, 2021** | $**10394** | $**1659** | $**21** | $**(97)** | $**11977** |
| NPM Adjustment Items - 2021 | (53) |  |  |  | (53) |
| Asset impairment, exit, implementation, acquisition and disposition-related costs - 2021 |  | 37 | 52 |  | 89 |
| Tobacco and health and certain other litigation items - 2021 | 83 |  |  |  | 83 |
|  | 30 | 37 | 52 |  | 119 |
| NPM Adjustment Items - 2022 | 63 |  |  |  | 63 |
| Tobacco and health and certain other litigation items - 2022 | (101) |  |  |  | (101) |
|  | (38) |  |  |  | (38) |
| Operations | 302 | (64) | (73) | 61 | 226 |
| **For the year ended December 31, 2022** | $**10688** | $**1632** | $**—** | $**(36)** | $**12284** |

---

------

---

| | | | | |
|:---|:---|:---|:---|:---|
| Schedule 5 | Schedule 5 | Schedule 5 | Schedule 5 | Schedule 5 |
| ALTRIA GROUP, INC. | ALTRIA GROUP, INC. | ALTRIA GROUP, INC. | ALTRIA GROUP, INC. | ALTRIA GROUP, INC. |
| and Subsidiaries | and Subsidiaries | and Subsidiaries | and Subsidiaries | and Subsidiaries |
| Supplemental Financial Data | Supplemental Financial Data | Supplemental Financial Data | Supplemental Financial Data | Supplemental Financial Data |
| (dollars in millions) | (dollars in millions) | (dollars in millions) | (dollars in millions) | (dollars in millions) |
| (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) |
|  | **For the Quarters Ended December 31,** | **For the Quarters Ended December 31,** | **For the Years Ended December 31,** | **For the Years Ended December 31,** |
|  | **2022** | **2021** | **2022** | **2021** |
| **The segment detail of excise taxes on products sold is as follows:** |  |  |  |  |
| Smokeable products | $1000 | $1134 | $4289 | $4754 |
| Oral tobacco products | 28 | 34 | 119 | 132 |
| Wine |  |  |  | 14 |
| All other |  | 1 |  | 2 |
|  | $1028 | $1169 | $4408 | $4902 |
| **The segment detail of charges for resolution expenses related to state settlement agreements included in cost of sales is as follows:** |  |  |  |  |
| Smokeable products | $922 | $1086 | $3908 | $4269 |
| Oral tobacco products | 3 | 2 | 10 | 9 |
| All other |  | 1 |  | 2 |
|  | $925 | $1089 | $3918 | $4280 |
| &nbsp;&nbsp;&nbsp;&nbsp;**The segment detail of FDA user fees included in cost of sales is** <br>**as follows:** |  |  |  |  |
| Smokeable products | $66 | $67 | $270 | $273 |
| Oral tobacco products | 1 | 2 | 5 | 5 |
|  | $67 | $69 | $275 | $278 |
| **The detail of (income) losses from investments in equity securities is as follows:** |  |  |  |  |
| ABI | $(182) | $(80) | $1973 | $5564 |
| Cronos | 16 | 270 | 213 | 415 |
| JUUL | 100 |  | 1455 |  |
|  | $(66) | $190 | $3641 | $5979 |

---

&nbsp;&nbsp;&nbsp;&nbsp;

------

---

| | | |
|:---|:---|:---|
| | | Schedule 6 |
| ALTRIA GROUP, INC. | ALTRIA GROUP, INC. | ALTRIA GROUP, INC. |
| and Subsidiaries | and Subsidiaries | and Subsidiaries |
| Net Earnings and Diluted Earnings Per Share - Attributable to Altria Group, Inc. | Net Earnings and Diluted Earnings Per Share - Attributable to Altria Group, Inc. | Net Earnings and Diluted Earnings Per Share - Attributable to Altria Group, Inc. |
| For the Quarters Ended December 31, | For the Quarters Ended December 31, | For the Quarters Ended December 31, |
| (dollars in millions, except per share data) | (dollars in millions, except per share data) | (dollars in millions, except per share data) |
| (Unaudited) | (Unaudited) | (Unaudited) |
|  | **Net Earnings** | **Diluted EPS** |
| **2022 Net Earnings** | $**2690** | $**1.50** |
| **2021 Net Earnings** | $**1624** | $**0.88** |
| **% Change** | **65.6%** | **70.5%** |
| **<u>Reconciliation:</u>** |  |  |
| **2021 Net Earnings** | $**1624** | $**0.88** |
| &nbsp;&nbsp;&nbsp;&nbsp;2021 Asset impairment, exit, implementation, acquisition and <br>disposition-related costs | 4 |  |
| 2021 Tobacco and health and certain other litigation items | 25 | 0.02 |
| 2021 ABI-related special items | 73 | 0.04 |
| 2021 Cronos-related special items | 265 | 0.15 |
| 2021 Income tax items | 2 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Subtotal 2021 special items | 369 | 0.21 |
| 2022 NPM Adjustment Items | 6 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;2022 Asset impairment, exit, implementation, acquisition and <br>disposition-related costs | (1) |  |
| 2022 Tobacco and health and certain other litigation items | (22) | (0.01) |
| 2022 JUUL changes in fair value | (100) | (0.06) |
| 2022 ABI-related special items | 12 |  |
| 2022 Cronos-related special items | (14) |  |
| 2022 Income tax items | 696 | 0.39 |
| &nbsp;&nbsp;&nbsp;&nbsp;Subtotal 2022 special items | 577 | 0.32 |
| Fewer shares outstanding |  | 0.03 |
| Change in tax rate | 14 |  |
| Operations | 106 | 0.06 |
| **2022 Net Earnings** | $**2690** | $**1.50** |

---

------

&nbsp;&nbsp;&nbsp;&nbsp;

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | | | | Schedule 7 | Schedule 7 |
| ALTRIA GROUP, INC. | ALTRIA GROUP, INC. | ALTRIA GROUP, INC. | ALTRIA GROUP, INC. | ALTRIA GROUP, INC. | ALTRIA GROUP, INC. |
| and Subsidiaries | and Subsidiaries | and Subsidiaries | and Subsidiaries | and Subsidiaries | and Subsidiaries |
| Reconciliation of GAAP and non-GAAP Measures | Reconciliation of GAAP and non-GAAP Measures | Reconciliation of GAAP and non-GAAP Measures | Reconciliation of GAAP and non-GAAP Measures | Reconciliation of GAAP and non-GAAP Measures | Reconciliation of GAAP and non-GAAP Measures |
| For the Quarters Ended December 31, | For the Quarters Ended December 31, | For the Quarters Ended December 31, | For the Quarters Ended December 31, | For the Quarters Ended December 31, | For the Quarters Ended December 31, |
| (dollars in millions, except per share data) | (dollars in millions, except per share data) | (dollars in millions, except per share data) | (dollars in millions, except per share data) | (dollars in millions, except per share data) | (dollars in millions, except per share data) |
| (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) |
|  | **Earnings before Income Taxes** | **Provision for Income Taxes** | **Net Earnings** | **Net Earnings Attributable to Altria** | **Diluted EPS** |
| **2022 Reported** | $**2704** | $**14** | $**2690** | $**2690** | $**1.50** |
| NPM Adjustment Items | (8) | (2) | (6) | (6) |  |
| Asset impairment, exit, implementation, acquisition and disposition-related costs | 1 |  | 1 | 1 |  |
| Tobacco and health and certain other litigation items  | 30 | 8 | 22 | 22 | 0.01 |
| JUUL changes in fair value | 100 |  | 100 | 100 | 0.06 |
| ABI-related special items | (16) | (4) | (12) | (12) |  |
| Cronos-related special items | 6 | (8) | 14 | 14 |  |
| Income tax items |  | 696 | (696) | (696) | (0.39) |
| **2022 Adjusted for Special Items** | $**2817** | $**704** | $**2113** | $**2113** | $**1.18** |
| **2021 Reported** | $**2280** | $**656** | $**1624** | $**1624** | $**0.88** |
| Asset impairment, exit, implementation, acquisition and disposition-related costs | 3 | (1) | 4 | 4 |  |
| Tobacco and health and certain other litigation items | 34 | 9 | 25 | 25 | 0.02 |
| ABI-related special items | 92 | 19 | 73 | 73 | 0.04 |
| Cronos-related special items | 266 | 1 | 265 | 265 | 0.15 |
| Income tax items |  | (2) | 2 | 2 |  |
| **2021 Adjusted for Special Items** | $**2675** | $**682** | $**1993** | $**1993** | $**1.09** |
| **2022 Reported Net Earnings** |  |  |  | $**2690** | $**1.50** |
| **2021 Reported Net Earnings** |  |  |  | $**1624** | $**0.88** |
| **% Change** |  |  |  | **65.6%** | **70.5%** |
| **2022 Net Earnings Adjusted for Special Items** |  |  |  | $**2113** | $**1.18** |
| **2021 Net Earnings Adjusted for Special Items** |  |  |  | $**1993** | $**1.09** |
| **% Change** |  |  |  | **6.0%** | **8.3%** |

---

------

---

| | | |
|:---|:---|:---|
| | | Schedule 8 |
| ALTRIA GROUP, INC. | ALTRIA GROUP, INC. | ALTRIA GROUP, INC. |
| and Subsidiaries | and Subsidiaries | and Subsidiaries |
| Net Earnings and Diluted Earnings Per Share - Attributable to Altria Group, Inc. | Net Earnings and Diluted Earnings Per Share - Attributable to Altria Group, Inc. | Net Earnings and Diluted Earnings Per Share - Attributable to Altria Group, Inc. |
| For the Years Ended December 31, | For the Years Ended December 31, | For the Years Ended December 31, |
| (dollars in millions, except per share data) | (dollars in millions, except per share data) | (dollars in millions, except per share data) |
| (Unaudited) | (Unaudited) | (Unaudited) |
|  | **Net Earnings** | **Diluted EPS**<sup>1</sup>  |
| **2022 Net Earnings** | $**5764** | $**3.19** |
| **2021 Net Earnings** | $**2475** | $**1.34** |
| **% Change** | **100%+** | **100%+** |
| **<u>Reconciliation:</u>** |  |  |
| **2021 Net Earnings** | $**2475** | $**1.34** |
| 2021 NPM Adjustment Items | (57) | (0.03) |
| 2021 Asset impairment, exit, implementation, acquisition and <br>&nbsp;&nbsp;&nbsp;&nbsp;disposition-related costs | 99 | 0.05 |
| 2021 Tobacco and health and certain other litigation items | 138 | 0.07 |
| 2021 ABI-related special items | 4901 | 2.66 |
| 2021 Cronos-related special items | 470 | 0.25 |
| 2021 Loss on early extinguishment of debt | 496 | 0.27 |
| 2021 Income tax items | (3) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Subtotal 2021 special items | 6044 | 3.27 |
| 2022 NPM Adjustment Items | 51 | 0.03 |
| 2022 Asset impairment, exit, implementation, acquisition and <br>&nbsp;&nbsp;&nbsp;&nbsp;disposition-related costs | (9) |  |
| 2022 Tobacco and health and certain other litigation items | (98) | (0.05) |
| 2022 JUUL changes in fair value | (1455) | (0.81) |
| 2022 ABI-related special items | (2010) | (1.12) |
| 2022 Cronos-related special items | (186) | (0.10) |
| 2022 Income tax items | 729 | 0.40 |
| &nbsp;&nbsp;&nbsp;&nbsp;Subtotal 2022 special items | (2978) | (1.65) |
| Fewer shares outstanding |  | 0.11 |
| Change in tax rate | 14 |  |
| Operations | 209 | 0.12 |
| **2022 Net Earnings** | $**5764** | $**3.19** |
| <sup>1</sup> Diluted earnings per share attributable to Altria are computed independently for each period. Accordingly, the sum of the quarterly earnings per share amounts may not agree to the year-to-date amounts. | <sup>1</sup> Diluted earnings per share attributable to Altria are computed independently for each period. Accordingly, the sum of the quarterly earnings per share amounts may not agree to the year-to-date amounts. | <sup>1</sup> Diluted earnings per share attributable to Altria are computed independently for each period. Accordingly, the sum of the quarterly earnings per share amounts may not agree to the year-to-date amounts. |

---

es) per share attributable to Altria are computed independently for each period. Accordingly, t

------

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | | | | Schedule 9 | Schedule 9 |
| ALTRIA GROUP, INC. | ALTRIA GROUP, INC. | ALTRIA GROUP, INC. | ALTRIA GROUP, INC. | ALTRIA GROUP, INC. | ALTRIA GROUP, INC. |
| and Subsidiaries | and Subsidiaries | and Subsidiaries | and Subsidiaries | and Subsidiaries | and Subsidiaries |
| Reconciliation of GAAP and non-GAAP Measures | Reconciliation of GAAP and non-GAAP Measures | Reconciliation of GAAP and non-GAAP Measures | Reconciliation of GAAP and non-GAAP Measures | Reconciliation of GAAP and non-GAAP Measures | Reconciliation of GAAP and non-GAAP Measures |
| For the Years Ended December 31, | For the Years Ended December 31, | For the Years Ended December 31, | For the Years Ended December 31, | For the Years Ended December 31, | For the Years Ended December 31, |
| (dollars in millions, except per share data) | (dollars in millions, except per share data) | (dollars in millions, except per share data) | (dollars in millions, except per share data) | (dollars in millions, except per share data) | (dollars in millions, except per share data) |
| (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) |
|  | **Earnings before Income Taxes** | **Provision for Income Taxes** | **Net Earnings** | **Net Earnings Attributable to Altria** | **Diluted EPS**<sup>1</sup>  |
| **2022 Reported** | $**7389** | $**1625** | $**5764** | $**5764** | $**3.19** |
| NPM Adjustment Items | (68) | (17) | (51) | (51) | (0.03) |
| Asset impairment, exit, implementation, acquisition and disposition-related costs | 11 | 2 | 9 | 9 |  |
| Tobacco and health and certain other litigation items | 131 | 33 | 98 | 98 | 0.05 |
| JUUL changes in fair value | 1455 |  | 1455 | 1455 | 0.81 |
| ABI-related special items | 2544 | 534 | 2010 | 2010 | 1.12 |
| Cronos-related special items | 186 |  | 186 | 186 | 0.10 |
| Income tax items |  | 729 | (729) | (729) | (0.40) |
| **2022 Adjusted for Special Items** | $**11648** | $**2906** | $**8742** | $**8742** | $**4.84** |
| **2021 Reported** | $**3824** | $**1349** | $**2475** | $**2475** | $**1.34** |
| NPM Adjustment Items | (76) | (19) | (57) | (57) | (0.03) |
| Asset impairment, exit, implementation, acquisition and disposition-related costs | 120 | 21 | 99 | 99 | 0.05 |
| Tobacco and health and certain other litigation items | 182 | 44 | 138 | 138 | 0.07 |
| ABI-related special items | 6203 | 1302 | 4901 | 4901 | 2.66 |
| Cronos-related special items | 466 | (4) | 470 | 470 | 0.25 |
| Loss on early extinguishment of debt | 649 | 153 | 496 | 496 | 0.27 |
| Income tax items |  | 3 | (3) | (3) |  |
| **2021 Adjusted for Special Items** | $**11368** | $**2849** | $**8519** | $**8519** | $**4.61** |
| **2022 Reported Net Earnings** |  |  |  | $**5764** | $**3.19** |
| **2021 Reported Net Earnings** |  |  |  | $**2475** | $**1.34** |
| **% Change** |  |  |  | **100%+** | **100%+** |
| **2022 Net Earnings Adjusted for Special Items** |  |  |  | $**8742** | $**4.84** |
| **2021 Net Earnings Adjusted for Special Items** |  |  |  | $**8519** | $**4.61** |
| **% Change** |  |  |  | **2.6%** | **5.0%** |
| <sup>1</sup> Diluted earnings per share attributable to Altria are computed independently for each period. Accordingly, the sum of the quarterly earnings per share amounts may not agree to the year-to-date amounts. | <sup>1</sup> Diluted earnings per share attributable to Altria are computed independently for each period. Accordingly, the sum of the quarterly earnings per share amounts may not agree to the year-to-date amounts. | <sup>1</sup> Diluted earnings per share attributable to Altria are computed independently for each period. Accordingly, the sum of the quarterly earnings per share amounts may not agree to the year-to-date amounts. | <sup>1</sup> Diluted earnings per share attributable to Altria are computed independently for each period. Accordingly, the sum of the quarterly earnings per share amounts may not agree to the year-to-date amounts. | <sup>1</sup> Diluted earnings per share attributable to Altria are computed independently for each period. Accordingly, the sum of the quarterly earnings per share amounts may not agree to the year-to-date amounts. | <sup>1</sup> Diluted earnings per share attributable to Altria are computed independently for each period. Accordingly, the sum of the quarterly earnings per share amounts may not agree to the year-to-date amounts. |

---

<sup>1</sup> Basic and diluted earnings (losses) per share attributable to Altria are computed independently for each period. Accordingly, the sum of the quarterly earnings (losses) per share amounts may not agree to the year-to-date amounts

------

---

| | | |
|:---|:---|:---|
| | | Schedule 10 |
| ALTRIA GROUP, INC. | ALTRIA GROUP, INC. | ALTRIA GROUP, INC. |
| and Subsidiaries | and Subsidiaries | and Subsidiaries |
| Condensed Consolidated Balance Sheets | Condensed Consolidated Balance Sheets | Condensed Consolidated Balance Sheets |
| (dollars in millions) | (dollars in millions) | (dollars in millions) |
| (Unaudited) | (Unaudited) | (Unaudited) |
|  | **December 31, 2022** | **December 31, 2021** |
| **<u>Assets</u>** |  |  |
| Cash and cash equivalents | $4030 | $4544 |
| Receivable from the sale of *IQOS* System commercialization rights | 1721 |  |
| Inventories | 1180 | 1194 |
| Other current assets | 289 | 345 |
| Property, plant and equipment, net | 1608 | 1553 |
| Goodwill and other intangible assets, net | 17561 | 17483 |
| Investments in equity securities | 9600 | 13481 |
| Other long-term assets | 965 | 923 |
| **Total assets** | $**36954** | $**39523** |
| **<u>Liabilities and Stockholders' Equity (Deficit)</u>** |  |  |
| Current portion of long-term debt | $1556 | $1105 |
| Accrued settlement charges | 2925 | 3349 |
| Other current liabilities | 4135 | 4125 |
| Long-term debt | 25124 | 26939 |
| Deferred income taxes | 2897 | 3692 |
| Accrued pension costs | 133 | 200 |
| Accrued postretirement health care costs | 1083 | 1436 |
| Deferred gain from the sale of *IQOS* System commercialization rights | 2700 |  |
| Other long-term liabilities | 324 | 283 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total liabilities | 40877 | 41129 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total stockholders' equity (deficit) | (3973) | (1606) |
| &nbsp;&nbsp;&nbsp;&nbsp; Noncontrolling interest | 50 |  |
| **Total liabilities and stockholders' equity (deficit)** | $**36954** | $**39523** |
| Total debt | $26680 | $28044 |

---

------

&nbsp;&nbsp;&nbsp;&nbsp;

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | | | | | | Schedule 11 |
| ALTRIA GROUP, INC. | ALTRIA GROUP, INC. | ALTRIA GROUP, INC. | ALTRIA GROUP, INC. | ALTRIA GROUP, INC. | ALTRIA GROUP, INC. | ALTRIA GROUP, INC. |
| and Subsidiaries | and Subsidiaries | and Subsidiaries | and Subsidiaries | and Subsidiaries | and Subsidiaries | and Subsidiaries |
| Supplemental Financial Data for Special Items | Supplemental Financial Data for Special Items | Supplemental Financial Data for Special Items | Supplemental Financial Data for Special Items | Supplemental Financial Data for Special Items | Supplemental Financial Data for Special Items | Supplemental Financial Data for Special Items |
| For the Quarters Ended December 31,  | For the Quarters Ended December 31,  | For the Quarters Ended December 31,  | For the Quarters Ended December 31,  | For the Quarters Ended December 31,  | For the Quarters Ended December 31,  | For the Quarters Ended December 31,  |
| (dollars in millions) | (dollars in millions) | (dollars in millions) | (dollars in millions) | (dollars in millions) | (dollars in millions) | (dollars in millions) |
| (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) |
|  | **Cost of<br>Sales** | **Marketing, <br>administration <br>and research costs** | **General<br>corporate<br>expenses** | **Interest and other debt (income) expense, net** | **(Income) losses from <br>investments in equity securities** | **Loss on Cronos-related financial instruments** |
| **2022 Special Items - (Income) Expense** |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;NPM Adjustment Items | $(3) | $— | $— | $(5) | $— | $— |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Asset impairment, exit, implementation, acquisition and <br>disposition-related costs |  |  | 22 | (21) |  |  |
| &nbsp;&nbsp;&nbsp;Tobacco and health and certain other litigation items |  | 30 |  |  |  |  |
| &nbsp;&nbsp;&nbsp;JUUL changes in fair value |  |  |  |  | 100 |  |
| &nbsp;&nbsp;&nbsp;ABI-related special items |  |  |  |  | (16) |  |
| &nbsp;&nbsp;&nbsp;Cronos-related special items |  |  |  |  | 5 | 1 |
| **2021 Special Items - (Income) Expense** |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Asset impairment, exit, implementation, acquisition and <br>disposition-related costs | $— | $— | $3 | $— | $— | $— |
| &nbsp;&nbsp;&nbsp;Tobacco and health and certain other litigation items |  | 11 | 20 | 3 |  |  |
| &nbsp;&nbsp;&nbsp;ABI-related special items |  |  |  |  | 92 |  |
| &nbsp;&nbsp;&nbsp;Cronos-related special items |  |  |  |  | 246 | 20 |

---

Note: This schedule is intended to provide supplemental financial data for certain income and expense items that management believes are not part of underlying operations and their presentation in Altria's consolidated statements of earnings. This schedule is not intended to provide, or reconcile, non-GAAP financial measures.

------

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| | | | | | | Schedule 12 | Schedule 12 |
| ALTRIA GROUP, INC. | ALTRIA GROUP, INC. | ALTRIA GROUP, INC. | ALTRIA GROUP, INC. | ALTRIA GROUP, INC. | ALTRIA GROUP, INC. | ALTRIA GROUP, INC. | ALTRIA GROUP, INC. |
| and Subsidiaries | and Subsidiaries | and Subsidiaries | and Subsidiaries | and Subsidiaries | and Subsidiaries | and Subsidiaries | and Subsidiaries |
| Supplemental Financial Data for Special Items | Supplemental Financial Data for Special Items | Supplemental Financial Data for Special Items | Supplemental Financial Data for Special Items | Supplemental Financial Data for Special Items | Supplemental Financial Data for Special Items | Supplemental Financial Data for Special Items | Supplemental Financial Data for Special Items |
| For the Years Ended December 31, | For the Years Ended December 31, | For the Years Ended December 31, | For the Years Ended December 31, | For the Years Ended December 31, | For the Years Ended December 31, | For the Years Ended December 31, | For the Years Ended December 31, |
| (dollars in millions) | (dollars in millions) | (dollars in millions) | (dollars in millions) | (dollars in millions) | (dollars in millions) | (dollars in millions) | (dollars in millions) |
| (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) | (Unaudited) |
|  | **Cost of<br>Sales** | **Marketing, administration and research costs** | **General corporate expenses** | **Interest and other debt (income) expense, net** | **Loss on early extinguishment of debt** | **(Income) losses from investments in equity securities** | **Loss on Cronos-related financial instruments** |
| **2022 Special Items - (Income) Expense** |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;NPM Adjustment Items | $(63) | $— | $— | $(5) | $— | $— | $— |
| &nbsp;&nbsp;&nbsp;Asset impairment, exit, implementation, acquisition and disposition-related costs |  |  | 32 | (21) |  |  |  |
| &nbsp;&nbsp;&nbsp;Tobacco and health and certain other litigation items |  | 101 | 27 | 3 |  |  |  |
| &nbsp;&nbsp;&nbsp;JUUL changes in fair value |  |  |  |  |  | 1455 |  |
| &nbsp;&nbsp;&nbsp;ABI-related special items |  |  |  |  |  | 2544 |  |
| &nbsp;&nbsp;&nbsp;Cronos-related special items |  |  |  |  |  | 171 | 15 |
| **2021 Special Items - (Income) Expense** |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;NPM Adjustment Items | $(53) | $— | $— | $(23) | $— | $— | $— |
| &nbsp;&nbsp;&nbsp;Asset impairment, exit, implementation, acquisition and disposition-related costs | 1 | 88 | 31 |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Tobacco and health and certain other litigation items |  | 83 | 90 | 9 |  |  |  |
| &nbsp;&nbsp;&nbsp;ABI-related special items |  |  |  |  |  | 6203 |  |
| &nbsp;&nbsp;&nbsp;Cronos-related special items |  |  |  |  |  | 318 | 148 |
| &nbsp;&nbsp;&nbsp;Loss on early extinguishment of debt |  |  |  |  | 649 |  |  |

---

Note: This schedule is intended to provide supplemental financial data for certain income and expense items that management believes are not part of underlying operations and their presentation in our consolidated statements of earnings (losses). This schedule is not intended to provide, or reconcile, non-GAAP financial measures.

<br>